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OBJECTIVES This study sought to assess the incidence of transplant coronary artery disease (CAD) in
Chinese heart recipients.
BACKGROUND The prevalence of transplant CAD detected by angiography at 1, 2 and 4 years after heart
transplantation was 11%, 22% and 45%, respectively. The incidence of transplant CAD in
Chinese heart recipients has not been reported.
METHODS For those recipients surviving for more than 1 year after transplantation, coronary angiogra-
phy was performed annually for surveillance of transplant CAD. The recipient characteristics,
donor characteristics, rejection episodes, medication and human leukocyte antigen (HLA)
mismatches were recorded.
RESULTS Fifty patients were included in this study. Thirteen (26%) recipients had ischemic heart
disease. Two patients (4%) had active cytomegalovirus (CMV) infection after transplantation.
The mean number of rejection episodes in the 1st year after transplantation was 1.15. Among
47 patients with complete data of donor and recipient histocompatibility antigens, there were
seven patients (14.9%) with two or fewer HLA mismatches. Among 74 angiograms of 50
patients reviewed, only one patient had discrete stenosis less than 50% in the middle portion
of the left anterior descending artery at 1 year after transplantation. The cumulative incidence
of transplant CAD was 2% at 1 year and 2% at 2 and 4 years after transplantation.
CONCLUSIONS The incidence of transplant CAD was low in Chinese heart transplant recipients. Low
percentage of ischemic heart disease in recipients, low occurrence of active CMV infection
and rejection episodes after transplantation, less racial disparity, and lower HLA mismatches
may be the important factors. (J Am Coll Cardiol 1999;33:1573–7) © 1999 by the American
College of Cardiology
Advances in immunosuppressive therapy have reduced early
mortality due to acute rejection and infection (1,2). How-
ever, transplant coronary artery disease (CAD) was still the
major cause of mortality and morbidity in the long-term
survivors of heart transplants (3–9). The prevalence of
transplant CAD detected by angiography at 1, 2 and 4 years
after transplantation was 11%, 22% and 45% (9). In Asia,
the first clinical heart transplantation was performed by
Wada in 1968. Because of poor result, no active heart
transplantation program proceeded for two decades. In July
1987, the first heart transplantation was started in Taiwan
(10). The aim of this study was to assess the incidence of
transplant CAD in Chinese heart recipients.
METHODS
Patients and treatment. From October 1987 to June 1998,
we had performed 92 cases of heart transplantation at the
National Taiwan University Hospital. Eight-eight patients
underwent orthotopic heart transplantation. Since 1997, we
have used bicaval anastomosis, instead of standard midatrial
anastomosis, for orthotopic transplantation especially in
patients with high pulmonary vascular resistance. There
were four cases of heterotopic heart transplantation for
donor/recipient size mismatch in two (11), poor donor heart
function in one and high pulmonary vascular resistance
before transplantation in one patient. There were two cases
of successful simultaneous heart and kidney transplantation.
One case with Marfan syndrome had successful combined
heart transplantation and resection of dissecting aortic
aneurysm of ascending aorta and aortic arch. Three patients
had mechanical bridge to heart transplantation successfully
using the Thoratec ventricular assist device. Postoperatively,
we used extracorporeal membrane oxygenation for acute
allograft failure in eight patients. Three of eight patients
were successfully weaned and discharged.
From the *Department of Surgery and †Department of Internal Medicine,
National Taiwan University Hospital, Taipei, Taiwan. This study was supported in
part by grant 88N108 from National Taiwan University Hospital.
Manuscript received July 31, 1998; revised manuscript received January 8, 1999,
accepted January 21, 1999.
Journal of the American College of Cardiology Vol. 33, No. 6, 1999
© 1999 by the American College of Cardiology ISSN 0735-1097/99/$20.00
Published by Elsevier Science Inc. PII S0735-1097(99)00060-1
All patients received triple-drug immunosuppressive
therapy according to our heart transplantation protocol.
Since 1995, we have used rabbit antithymocyte globulins for
induction therapy. Azathioprine (4 mg/kg) was given 1 h
before the operation. Solumedrol (1,000 mg) was infused
during release of the aortic cross clamp. Rabbit antithymo-
cyte globulin 1.5 to 2.5 mg/kg/day was given after trans-
plantation for 5 days. Cyclosporine was started orally within
5 days after transplantation or after the recovery of renal
function. Cyclosporine dose was adjusted according to renal
function and serum cyclosporine level, which was main-
tained at the trough level of 300 to 500 ng/ml during the
first 3 months after transplantation and 200 to 300 ng/ml 1
year after transplantation. Azathioprine was given at 1 to 2
mg/kg/day after transplantation, with the dose adjusted to
maintain a white blood cell count 4,000 to 6,000/mm3.
Prednisone (0.5 mg/kg/day) was started on the second
postoperative day and tapered to 0.2 mg/kg/day by the 1st
month after transplantation. Endomyocardial biopsy was
performed weekly in the first month, biweekly in the second
month, monthly in the sixth month and yearly six months
after transplantation. Tacrolimus (FK-506) and mycophe-
nolate mofetil (Cellcept) were used for recurrent rejection or
severe adverse reactions to cyclosporine and azathioprine.
All patients discharged received 100 mg aspirin daily and
25 mg dipyridamole three times per day for prevention of
transplant CAD. Hyperlipidemia was treated with dietary
modification and body weight control first. Hypertriglycer-
idemia was treated with bezafibrate. Hypercholesterolemia
was treated with pravastatin and acipimox. Hyperuricemia
was treated with probenecid and allopurinol. Hyperglycemia
was treated with oral hypoglycemic agent and insulin.
Hypertension was treated with angiotensin-converting en-
zyme inhibitors and calcium antagonists. All patients were
followed at a special cardiac transplant clinic.
Data collection. For those patients surviving for more than
six months after transplantation, coronary angiography and
endomyocardial biopsy were performed annually for surveil-
lance of transplant CAD. The coronary angiogram per-
formed 1 month after transplantation was used for baseline
data. Cineangiograms were recorded at 60 frames/s through
a lens with a focal length of 135 mm and with an X-ray field
of 15 cm. Multiple pairs of perpendicular views of the left
and right coronary arteries were taken. All coronary angio-
grams were reviewed by two cardiologists in a blinded
fashion. Coronary lesions were evaluated by on-line digital
quantitative coronary angiograms (DCI System, Philips,
Best, The Netherlands) (12). The intraobserver and inter-
observer variations were 5% and 8%, respectively. The
diagnosis of transplant CAD was made from the evidence of
any coronary artery irregularity or diffuse narrowing in
proximal and distal vessels. Transplant CAD was classified
as localized atherosclerotic lesions or diffuse concentric
narrowing. Endomyocardial biopsy was examined for isch-
emic myocardial pathology. Cardiac events including myo-
cardial infarction, left ventricular dysfunction, arrhythmia
and sudden death were recorded. The recipient character-
istics (age, gender, body weight, smoking, hypertension,
diabetes, cholesterol level, triglyceride level and viral infec-
tion), donor characteristics (age, gender, preexisting coro-
nary artery disease and allograft ischemic time), rejection
episodes, medications and human leukocyte antigen (HLA)
match were recorded. Cytomegalovirus (CMV) infection
was defined as a fourfold rise in antibody, CMV inclusion
body or positive culture. Rejection was defined as biopsy-
proven pathologic finding and clinical event leading to
specific immunosuppressive intervention.
Statistical analysis. Comparisons between groups were
determined by the two-tailed t test for difference in propor-
tion and means. A difference of p , 0.05 was considered
statistically significant.
RESULTS
Among these 92 heart transplant recipients, seven patients
died within the first month after transplantation because of
bleeding in 3, acute rejection in 2, arrhythmia in 1 and
cerebral injury in 1 patient. Another 10 patients died within
the first year after transplantation because of infection in 5,
rejection in 3 (two for medical noncompliance) and arrhyth-
mia and gastrointestinal bleeding each in one patient. The
operative mortality rate was 7.6%. The one-year survival
rate was 81.5%. Twenty-five of 92 cardiac transplant pa-
tients are alive less than 1 year after transplantation and
could not be evaluated for this study. At the time of this
study, obesity was present in 17, hypertension in 21,
hyperuricemia in 27, diabetes in 17, renal dysfunction in 21
and hyperlipidemia in 34 of 50 patients. No patients used
diltiazem. Pravastatin was used in 12 patients for hyperlip-
idemia.
Fifty patients survived for more than one year and were
included in this study. Among these 50 patients, there were
42 men and 8 women. The clinical diagnosis of end-stage
heart failure was idiopathic dilated cardiomyopathy in 31
(62%), ischemic heart disease in 13 (26%), valvular heart
disease in 4 (8%), congenital heart disease and postpartum
cardiomyopathy in 1 patient. The mean recipient age was
44.1 6 13.6 years at the time of transplantation. The mean
donor age was 29.4 6 10.8 years (range 15 to 55). Positive
CMV antibody was present in 44 of 48 recipients (91.7%)
and 27 of 30 donors (90%) at the time of transplantation.
The allograft ischemic time was 45 to 223 min (mean
101.1).
Rejection. Thirty-two patients had a biopsy-proven epi-
sode of acute rejection within the 1st year after transplan-
tation, with an incidence of rejection of 64% within 1 year
after transplantation. The mean number of rejection epi-
sodes in the 1st year after transplantation was 1.15. Among
the ninety-two cases of heart transplantation, two patients
had acute vascular rejection and died in spite of mechanical
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circulatory support, plasmapheresis and immunoadsorption
therapy. Rejection rarely occurred in patients more than one
year after transplantation. Only two recipients had late acute
rejection.
Infection. During the follow-up period, eight patients had
major infection. Among these 50 recipients, seven patients
(14%) were hepatitis B carriers. Three of seven carriers had
liver failure due to hepatitis B reactivation. Two patients
were treated successfully with lamivudine. One patient had
liver cirrhosis at eight years after transplantation. Two
patients (4%) had active CMV infection and were treated
with ganciclovir therapy. One patient had Aspergillus infec-
tion and was cured by amphotericin infusion and wedge
resection of infected lung (13). There was one patient with
malignant lymphoma of small intestine. No patient had
solid organ tumor or Kaposi sarcoma after transplantation.
Cardiac event. Cardiac events occurred in three patients.
One patient had atrial arrhythmia. One patient had biopsy-
negative left ventricular dysfunction and the coronary an-
giogram was patent. Another patient with heterotopic heart
transplantation had sudden arrest of donor heart. The
coronary artery was patent and the pathology was massive
coagulation necrosis. The patient was doing well for im-
proved native heart function due to prolonged unloading of
native heart after heterotopic heart transplantation.
Human leukocyte antigen mismatch. Complete HLA
information on the A, B and DR loci was available for both
donor and recipient in 47 patients. Seven patients (14.9%)
had two or fewer HLA mismatches, whereas three patients
(6.4%) had mismatches of all six HLA loci (Table 1).
Transplant CAD. Coronary angiography was reviewed by
at least two cardiologists at the time of study. Among 74
angiograms of 50 patients reviewed, only one patient had
discrete stenosis less than 50% in the middle part of the left
anterior descending artery at one year after transplantation.
This patient, a 39-year old man, was a case of ischemic heart
disease and received heart transplantation for end-stage
heart failure. He had two rejection episodes in the first year
after transplantation. No coronary angioplasty was per-
formed then, because he was free of angina and left
ventricular dysfunction. No patient had diffuse narrowing of
coronary artery. The cumulative incidence of transplant
CAD was 2% (1/50) at 1 year and 2% at 2 years (30 cases)
and 4 years (10 cases) after transplantation. In all specimens
of endomyocardial biopsy after 1 year posttransplant, there
was no evidence of ischemic myocardial pathology including
subendocardial myocyte vacuolization and coagulative myo-
cyte necrosis as described by Winters and Schoen (14).
DISCUSSION
Transplant CAD. Heart transplantation has become a
highly effective therapy for patients with end-stage heart
diseases. With advances in management of infectious com-
plications and immunosuppressive therapy, the survival after
heart transplantation continues to improve. In the 1993
Registry of the International Society for Heart and Lung
Transplantation, the one-year and five-year survival rates
after heart transplantation were 79.1% and 67.8% (15).
Although modern immunosuppressive therapy has reduced
death caused by acute rejection and infection, late mortality
as a result of transplant CAD remains an unresolved
problem (3–8). In a multi-institutional study (9), the
prevalence of transplant CAD detected by angiography was
11%, 22% and 45% at 1, 2 and 4 years after transplantation,
respectively. Transplant CAD is an accelerated form of
atherosclerosis, characterized by rapid development of inti-
mal hyperplasia and smooth muscle cell proliferation (16). It
accounts for 36% of deaths in patients who survive 1 year
after transplantation and for 60% of retransplantation
(17,18). Myocardial revascularization procedures, including
coronary angioplasty (19), coronary artery bypass (20) and
transmyocardial laser revascularization (21), have limited
role in the management of transplant CAD for diffuse
narrowing of distal coronary artery. Retransplantation is also
associated with higher mortality and morbidity (18). It is
imperative to understand the risk factors and pathogenesis
of transplant CAD and to prevent its development and
progression.
Heart transplantation in Asia. Asia has more than 50% of
the world’s population, but the number of heart transplan-
tation up to December 1996 was only 380 cases. This
number is quite small in contrast to the huge number
performed in America and Europe. The major problem has
been that the acceptance of the concept of brain death as the
definition of death of the patient is difficult for Oriental
people due to cultural and religious reasons. Most Chinese
people want to keep the whole body buried after death.
Although Taiwan is a small island with a population of 22
million, about half the number of heart transplantations in
Asia have been performed in Taiwan. This provided us a
chance to evaluate the incidence of transplant CAD in
Chinese heart recipients. In this study, the incidence of
transplant CAD in our patients was only 2% at 1 year and
none at 2 and 4 years after transplantation. This was much
lower compared with the Western series (3,9).
Table 1. Number of HLA Mismatches in A, B and DR Loci
HLA
Mismatches (n) Patients (n) %
0 0 0
1 2 4.3
2 5 10.6
3 8 17.0
4 18 38.3
5 11 23.4
6 3 6.4
Total 47 100.0
HLA 5 human leukocyte antigen.
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Risk factors. Numerous studies have investigated the pos-
sible risk factors for the development of transplant CAD
(3–8). Controversies still exist regarding donor and recipi-
ent factors which promote the development and progression
of CAD after transplantation. Both immunologic and
nonimmunologic factors could contribute to the occurrence
of transplant coronary artery disease. Older recipient age,
older donor age, male recipient, female donor, recipient
with ischemic heart disease, allograft ischemic time, CMV
infection, hyperlipidemia, obesity, immunosuppression,
acute rejection, prophylactic diltiazem use, HLA mis-
matches and racial disparity have been recognized as the risk
factors (3–9,22–25). In Table 2, we compare the donor and
recipient characteristics between our patients and Western
patients (3–8,24). The donor age, recipient age and per-
centage of male gender were the same. Pretransplant diag-
nosis of recipients in our study was less due to ischemic
heart disease. The prevalence of ischemic heart disease is
low in Oriental countries possibly due to low fat and high
vegetable diet.
Cytomegalovirus infection. Human CMV infection has
been recognized as a significant risk factor of transplant
CAD, and prophylactic ganciclovir therapy may protect
against the development of transplant CAD (3,22). In this
study, more than 90% of donors and recipients had positive
CMV antibody before transplantation. The incidence of
CMV mismatches between donors and recipients was also
low. The percentage of CMV seronegative recipients was
only 8.3% in this study. Thus the chance of primary CMV
infection after transplantation was reduced. In fact, people
in Taiwan usually had CMV infection by airborne trans-
mission before adulthood. This accounts for the high
incidence of past CMV infection before transplantation.
Human leukocyte antigen mismatch. Previous studies
have shown that HLA mismatches are associated with a
higher incidence and severity of transplant CAD (3,23).
The pathogenic mechanism of transplant CAD is thought
to be primarily immune-mediated. Both cellular and hu-
moral immunities are involved. Besides, race and donor/
recipient race mismatch may influence the development of
transplant CAD. African-Americans have increased early
mortality due to transplant CAD (24). In this study, the
donors and recipients were all Chinese except one white
donor from Ireland. Thus the race mismatch was only one
of 50 recipients. The HLA mismatch was also low in this
study. The incidence of HLA mismatches two or less in A,
B and DR loci was 14.9%, compared with 6% in Western
series (26).
Rejection. Previous studies have shown that the risk of
transplant CAD may be increased by acute graft rejection
(6,25). In this study, we used antithymocyte globulin for
induction and higher doses of cyclosporine for maintenance
immunosuppression. The incidence of rejection within one
year after transplantation was the same between this study
and Western series (26). But the mean number of rejection
Table 2. Comparison Between Taiwan and Western Series*
Taiwan
Western Series
(Reference) p Value
Recipient age (yr) 44.1 6 13.6 46.4 6 17.7 (8) NS
Donor age (yr) 29.4 6 10.8 27.2 6 13.7 (8) NS
Male (%) 84 86.7–89 (4,5) NS
Ischemic heart disease (%) 26 42.4 (8) 0.02
Allograft ischemic time (min) 101.1 6 41.9 96.8–170 (4,5,7,8) NS
Operative mortality (%) 7.6 9.2 (8) NS
Active CMV infection (%) 4 15.7–50 (4,7) , 0.005
HLA mismatches ,3 (%) 14.9 6 (25) 0.01
Rejection within 1 year (%) 63 64 (25) NS
Mean number of rejection episodes in
the 1st year after transplant
1.14 6 1.41 2.0 6 1.1 (5) , 0.005
Hypertension (%) 42 61.1 (8) 0.007
Diabetes mellitus (%) 34 16.1 (8) , 0.005
Hyperlipidemia (%) 68 26.3 (8) , 0.005
Pacemaker implantation (%) 0 6.4 (8) NS
Malignancy (%) 2 3.7 (8) NS
Renal dysfunction (%) 42 18.9 (8) , 0.005
Chronic liver disease (%) 6 1.0 (8) , 0.005
Transplant CAD at
1 year (%) 2 6.3–11 (8,9) 0.042
2 years (%) 2 22 (9) , 0.005
4 years (%) 2 45 (9) , 0.005
*Data of Western series from references 4–9,25.
CAD 5 coronary artery disease; CMV 5 cytomegalovirus; HLA 5 human leukocyte antigen.
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episodes in the first year after transplantation was 1.15. Low
number of rejection episodes after transplantation may be
the causative factor of low incidence of transplant CAD in
this study.
Several nonimmunologic factors could contribute to the
development of transplant CAD. In this study, the preva-
lence of diabetes mellitus, renal dysfunction and hyperlip-
idemia in recipients after one year posttransplant was higher
than in the Western series (8). It further indicated that the
low incidence of transplant CAD in Chinese heart recipi-
ents was significant, and that the development of transplant
CAD is genetic/immunologic.
Study limitation. The major limitation of this study was
relatively short follow-up (30 patients at 2 years and 10
patients at 4 years). It is important to continue this study
and see if these preliminary observations hold up.
Conclusions. This study confirms the low incidence of
transplant CAD in Chinese heart transplant recipients in
comparison with Western transplant patients. Low percent-
age of ischemic heart disease in recipients, low occurrence of
active CMV infection and rejection episodes after trans-
plantation, less racial disparity and lower HLA mismatches
may be the important factors.
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